Isarna Presents Positive Preclinical Results Supporting Development of ISTH0036 for the Treatment of Glaucoma
MUNICH--(BUSINESS WIRE)--Our preclinical data support the compound’s potential to protect glaucoma patients’ vision and we see other high medical need diseases that could potentially benefit from TGF-β-targeted treatment.
